Roberts Zachary's Form 4 filing
Allogene Therapeutics, Inc.ALLO · filed Jan 23, 2025
- Accession no.
- 0001737287-25-000003
- Filed
- Jan 23, 2025
- Trade date
- Jan 21, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $48.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Roberts ZacharyCIK 0001851044 | Officer (EVP of R&D) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 21, 2025 | Common Stock | SSaleDisposed | −27,199 | $1.78F2 | −$48,414.22 | 488,054 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.78 to $1.805, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with in the rage set forth above.
Referenced by the price of 1 transaction in Table I.
Remarks
Exhibits: Power of Attorney